PURPOSE: A population pharmacokinetic model was developed to describe dose-exposure relationships of methotrexate (MTX) in adults with lymphoid malignancy; this is in order to explore the interindividual variability in relationship with the different physiopathological variables. The final model was applied to the Bayesian estimation of MTX concentrations using two blood samples. METHODS: Fifty-one patients receiving 136 courses of MTX (1-6 per patient) were included in this study. The data was analysed using NONMEM software. A linear two-compartment model with linear elimination best described the data. Setting mean parameters values and variabilities to population values, we obtained Bayesian prediction of MTX pharmacokinetic parameters and concentrations. The predictive performance was evaluated by comparing the Bayesian estimated and observed concentrations and the Bayesian estimated parameters with the individual final model estimated parameters. RESULTS: The population pharmacokinetic parameters and the inter-subject variablities expressed as coefficient of variation were: the total body clearance CL, 7.1 l h-1 (22%), the volume of the central and peripheral compartments V1, 25.1 l (22.5%), V2, 2.7 l (64%), respectively, and the transfer constant Q, 2.7 (51%) l h-1. Inter-course variability was only significant on CL. Age and serum creatinine had significant effects on CL and was included in the final model. A good correlation was obtained between Bayesian estimated and experimental concentrations (r2=0.85).
PURPOSE: A population pharmacokinetic model was developed to describe dose-exposure relationships of methotrexate (MTX) in adults with lymphoid malignancy; this is in order to explore the interindividual variability in relationship with the different physiopathological variables. The final model was applied to the Bayesian estimation of MTX concentrations using two blood samples. METHODS: Fifty-one patients receiving 136 courses of MTX (1-6 per patient) were included in this study. The data was analysed using NONMEM software. A linear two-compartment model with linear elimination best described the data. Setting mean parameters values and variabilities to population values, we obtained Bayesian prediction of MTX pharmacokinetic parameters and concentrations. The predictive performance was evaluated by comparing the Bayesian estimated and observed concentrations and the Bayesian estimated parameters with the individual final model estimated parameters. RESULTS: The population pharmacokinetic parameters and the inter-subject variablities expressed as coefficient of variation were: the total body clearance CL, 7.1 l h-1 (22%), the volume of the central and peripheral compartments V1, 25.1 l (22.5%), V2, 2.7 l (64%), respectively, and the transfer constant Q, 2.7 (51%) l h-1. Inter-course variability was only significant on CL. Age and serum creatinine had significant effects on CL and was included in the final model. A good correlation was obtained between Bayesian estimated and experimental concentrations (r2=0.85).
Authors: Dolores Aumente; Dolores Santos Buelga; John C Lukas; Pedro Gomez; Antonio Torres; Maria José García Journal: Clin Pharmacokinet Date: 2006 Impact factor: 6.447
Authors: Karen D Wright; John C Panetta; Arzu Onar-Thomas; Wilburn E Reddick; Zoltan Patay; Ibrahim Qaddoumi; Alberto Broniscer; Giles Robinson; Frederick A Boop; Paul Klimo; Deborah Ward; Amar Gajjar; Clinton F Stewart Journal: Cancer Chemother Pharmacol Date: 2014-10-24 Impact factor: 3.333
Authors: Ryan J Beechinor; Patrick A Thompson; Michael F Hwang; Ryan C Vargo; Lisa R Bomgaars; Jacqueline G Gerhart; ZoAnn E Dreyer; Daniel Gonzalez Journal: Clin Pharmacokinet Date: 2019-07 Impact factor: 6.447
Authors: Jennifer L Pauley; John C Panetta; Kristine R Crews; Deqing Pei; Cheng Cheng; John McCormick; Scott C Howard; John T Sandlund; Sima Jeha; Raul Ribeiro; Jeffrey Rubnitz; Ching-Hon Pui; William E Evans; Mary V Relling Journal: Cancer Chemother Pharmacol Date: 2013-06-13 Impact factor: 3.333